Alliance Aims to Push Boundaries for Bioseparation

Austrian firm BIA Separations and The Centre for Bio Separations Technology (CBST) at India’s VIT University are combining their expertise to develop new bioseparation platforms and technologies, and establish a BioSeparations Platform of Excellence at CBST.

AstraZeneca, Accent Launch up to $1.1B+ Cancer Collaboration Targeting RNA-Modifying Proteins

By targeting proteins that modify RNA, Accent reasons, it can effectively apply the proven approach of enzyme-directed small molecule therapies to a new class of enzymes with the ability to impact RNA pathobiology.

Nanobody System Tags, Grabs, Drags Proteins in the Cell

Nanobody-based system used to control intracellular protein localization and investigate developmental biology

Leo Pharma to Acquire Bayer Prescription Dermatology Portfolio

Leo Pharma has agreed to acquire Bayer’s global prescription dermatology unit for an undisclosed price, the companies said, in a deal that expands the buyer’s focus on skin drugs.

EC Clears Antibiotic Effective Against MRSA

The EC cleared AstraZeneca’s Zinforo™ (ceftaroline fosamil) intravenous antibiotic for the treatment of adults with complicated skin and soft tissue infections (cSSTI) or community acquired pneumonia (CAP).

Syndax, Genentech Launch Cancer Immunotherapy Trial Collaboration

The Phase Ib/II trial will assess Syndax's entinostat in combination with Genentech's atezolizumab (MPDL3280A) in patients with triple-negative breast cancer.

Alzheimer’s Disease Toxicity Halted by Synthetic Peptides

Alzheimer’s disease (AD) is characterized by the formation of large, insoluble deposits, or plaques, of amyloid-β peptide (Aβ) in the brain. These plaques are...

Immunomic Licenses CMV-Targeting Tech from Annias for LAMP-Vax Cancer Vaccines

Company will combine immune response-enhancing platform with nucleic acid vaccine technology to develop immunotherapeutics for brain and other cancers that contain CMV

Ebola Vaccines

A Phase I clinical trial of an Ebola vaccine developed in Canada just began at the Walter Reed Army Institute of Research in the U.S. Another Phase I trial of an Ebola vaccine developed by the NIH’s National Institute of Allergy and Infectious Diseases has been launched in Mali. In light of the growing Ebola virus crisis when do you think such a vaccine will be available?

2017 Lasker Award Winners: HPV Vaccine Researchers, TOR Discoverer, and Planned...

Michael N. Hall, Ph.D., of the University of Basel and NIH researchers Douglas R. Lowy, M.D., and John T. Schiller, Ph.D. join Planned Parenthood as Lasker Award winners for 2017

Recently Featured

Scroll Up